普利特(002324.SZ)半年度淨利潤預降55%-70%
格隆匯7月14日丨普利特(002324.SZ)公佈,預計2021年半年度歸屬於上市公司股東的淨利潤8481.42萬元至12722.13萬元,同比下降55%-70%。原因是:
1、去年同期公司響應國家“抗疫”號召,成功開發口罩專用熔噴聚丙烯材料,該材料在去年二季度疫情期間銷售成果優異,對公司去年上半年利潤產生大幅度影響,公司自去年7月起已迴歸主營業務,不再銷售口罩專用熔噴聚丙烯材料;
2、報吿期,雖然公司汽車改性材料業務實現較好銷售及收入增長,但受到上游主要原料及輔料價格相較去年同期大幅增長,致使公司主營成本大幅增長,對公司淨利潤產生較大程度影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.